<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473406</url>
  </required_header>
  <id_info>
    <org_study_id>TRACE trial</org_study_id>
    <nct_id>NCT02473406</nct_id>
  </id_info>
  <brief_title>Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis</brief_title>
  <acronym>TRACE</acronym>
  <official_title>Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weiqin Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zunyi Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Affiliated Nanhua Hospital, University of South China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yijishan Hospital of Wannan Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Medical College of Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Shangqiu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infected pancreatic necrosis and its related septic complications are the major cause of&#xD;
      death in patients with acute pancreatitis, therefore prevention of pancreatic infection is of&#xD;
      great clinical value in the treatment of AP.&#xD;
&#xD;
      Immunosuppression and disorders characterized by decreased HLA-DR expression and unbalanced&#xD;
      CD3/CD4+/CD8+ T cells of PBMC are thought to be associated with the development of pancreatic&#xD;
      infection. Thymosin alpha 1 has been shown to have immunomodulatory properties and its&#xD;
      effects in preventing pancreatic infection was not well studied. To evaluate the effects of&#xD;
      TA1 use in the early phase on preventing pancreatic infection, immunomodulation and clinical&#xD;
      outcomes in patients with AP,we aimed to design this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Background &amp; Rationale:&#xD;
&#xD;
      Infected pancreatic necrosis and its related septic complications are the major cause of&#xD;
      death in patients with acute pancreatitis1, therefore prevention of pancreatic infection is&#xD;
      of great clinical value in the treatment of AP.&#xD;
&#xD;
      Immunosuppression and disorders characterized by decreased HLA-DR expression and unbalanced&#xD;
      CD3/CD4+/CD8+ T cells of PBMC are thought to be associated with the development of pancreatic&#xD;
      infection2, 3. Thymosin alpha 1 has been shown to have immunomodulatory properties and its&#xD;
      effects in preventing pancreatic infection was not well studied4.&#xD;
&#xD;
      Aim of This Study:&#xD;
&#xD;
      To evaluate the effects of TA1 use in the early phase on preventing pancreatic infection,&#xD;
      immunomodulation and clinical outcomes in patients with AP.&#xD;
&#xD;
      Sample Size Estimation:&#xD;
&#xD;
      The prevalence of pancreatic infection was reported to be around 25% in AP episodes. To&#xD;
      demonstrate a 40% reduction in the prevalence of pancreatic infection with 80% power at a&#xD;
      two-sided alpha level of .05, we projected an estimated sample size of 500 participants.&#xD;
      Considering possible 2% withdraw, we plan to randomize 510 patients in total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Actual">March 24, 2021</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of pancreatic infection:</measure>
    <time_frame>during the index admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of new-onset organ failure and new-onset persistent organ failure</measure>
    <time_frame>during the index admission</time_frame>
    <description>(SOFA score for respiration, cardiovascular, or renal system ≥2 ). New-onset is defined as events that occur after randomization and not present 24 hours before randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding requiring intervention</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal perforation or fistula requiring intervention</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pancreatic fistula</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New receipt of mechanical ventilation/renal replacement therapy /New receipt of vasoactive agents</measure>
    <time_frame>during the index admission</time_frame>
    <description>not applied 24 hours before randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The requirement for catheter drainage/Number of drainage procedures required</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The requirement for minimally-invasive debridement/Number of minimally invasive necrosectomy required</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The requirement for open surgery/Number of open surgery required</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care unit(ICU) stay/Length of hospital stay</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score/ CRP level/ HLA-DR level/ Lymphocyte count</measure>
    <time_frame>on day0, day7, and day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital cost.</measure>
    <time_frame>during the index admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection within 90 days after enrollment</measure>
    <time_frame>90 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality within 90 days after enrollment</measure>
    <time_frame>90 days after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Pancreatitis, Acute Necrotizing</condition>
  <arm_group>
    <arm_group_label>Thymosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymosin alpha 1 has been shown to have immunomodulatory properties</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin Alpha 1</intervention_name>
    <description>In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.</description>
    <arm_group_label>Thymosin</arm_group_label>
    <other_name>Thymosin Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Symptoms and signs of acute pancreatitis based on abdominal pain suggestive of AP,&#xD;
             serum amylase at least three times the upper limit of normal, and/or characteristic&#xD;
             findings of AP on computed tomography or less commonly magnetic resonance imaging&#xD;
             (MRI) or transabdominal ultrasonography according to the Revised Atlanta Criteria[15];&#xD;
&#xD;
          2. Less than one week from the onset of abdominal pain;&#xD;
&#xD;
          3. Age between 18 to 70 years old;&#xD;
&#xD;
          4. Acute Physiology and Chronic Health Evaluation(APACHE II) score ≥8 during the last 24&#xD;
             hours before enrollment&#xD;
&#xD;
          5. Balthazar CT score ≥5 (presence of pancreatic necrosis)[16].&#xD;
&#xD;
          6. Written informed consent obtained&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Pregnant pancreatitis;&#xD;
&#xD;
          2. History of chronic pancreatitis；&#xD;
&#xD;
          3. Malignancy related acute pancreatitis&#xD;
&#xD;
          4. Receiving early intervention or surgery due to abdominal compartment syndrome or other&#xD;
             reasons before admission；&#xD;
&#xD;
          5. Patients with a known history of severe cardiovascular, respiratory, renal or hepatic&#xD;
             diseases defined as (1) greater than New York Heart Association Class II heart&#xD;
             failure(Class II not included), (2) active myocardial ischemia or (3) cardiovascular&#xD;
             intervention within previous 60 days, (4) history of cirrhosis or (5) chronic kidney&#xD;
             disease with creatinine clearance&lt; 40 mL/min, or (6) chronic obstructive pulmonary&#xD;
             disease with requirement for home oxygen;&#xD;
&#xD;
          6. Patients with preexisting immune disorders such as AIDS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Weiqin, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, Chin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ke Lu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, Chin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhou Jing, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, Chin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Weiqin Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Pancreatitis, prevent,Necrotizing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Acute Necrotizing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

